Loading clinical trials...
Loading clinical trials...
A Phase 1/2A, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 (hCitH3-mAb) in Healthy Volunteers and in Patients With Mild-to-Moderate ARDS: Part A (Healthy Volunteers)
Conditions
Interventions
HT31-1
Saline (0.9%, sterile, for infusion)
Locations
1
United States
Virginia Commonwealth University (VCU Health)
Richmond, Virginia, United States
Start Date
March 1, 2026
Primary Completion Date
August 1, 2026
Completion Date
November 1, 2026
Last Updated
March 4, 2026
NCT06703073
NCT06701669
NCT06876415
NCT07165717
NCT06790875
NCT07351435
Lead Sponsor
HTIC, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions